Anthracyclines are the cornerstone of many chemotherapy regimens for a variety of cancers.
Unfortunately, their use is limited by a cumulative dose-dependent cardiotoxicity. Despite …

In the field of cardio-oncology, it is well recognised that despite the benefits of chemotherapy
in treating and possibly curing cancer, it can cause catastrophic damage to bystander …

Background: Cancer therapy–induced cardiomyopathy (CCM) is associated with cumulative
drug exposures and preexisting cardiovascular disorders. These parameters incompletely …

Anthracycline-induced cardiotoxicity (AIC) is a serious and common side effect of
anthracycline therapy. Identification of genes and genetic variants associated with AIC risk …

Despite the enhanced knowledge of the pathophysiology of heart failure (HF), it still remains
a serious syndrome with substantial morbidity, mortality, and frequent hospitalizations …

Anthracyclines are an integral part of chemotherapy regimens used to treat a variety of
childhood-onset and adult-onset cancers. However, the development of cardiac dysfunction …

Chemotherapy-related cardiac dysfunction is a significant side effect of anticancer treatment.
Risk stratification is based on clinical-and treatment-related risk factors that do not …

Improving cancer survival represents the most significant effect of precision medicine and
personalized molecular and immunologic therapeutics. Cardiovascular health becomes …

Background Despite known clinical risk factors, predicting anthracycline cardiotoxicity
remains challenging. Objectives This study sought to develop a clinical and genetic risk …

Breast cancer has become the most common cancer in the US and worldwide. While
advances in early detection and treatment have resulted in a 40% reduction in breast cancer …